Ann: Supporting Technology Readiness of Novel PoC Platform, page-3

SUPPORTING TECHNOLOGY READINESS OF NOVEL POC PLATFORM

21 April 2017

• Anteo successfully completes Milestone 1 and progresses to next phase of
its partnership study
• Initial studies demonstrate high detection sensitivity

Anteo Diagnostics Limited (ASX: ADO) recently formed a partnership with Planet
Innovation, Deakin University and DMTC to further the technology readiness of Planet
Innovation’s (Nplex) low cost, high sensitivity point of care diagnostic system using
breakthrough reader technology.

Anteo’s contribution and objectives in Milestone 1 were to successfully functionalise
nanoparticles requiring integration with Planet Innovation’s reader. Anteo has successfully
established, optimised and verified a model lateral flow system for the nominated target
assay using Mix&Go. Using the model lateral flow system, it has already matched and
possibly exceeded sensitivity benchmarks developed by a US based assay development
company. This benchmark has previously been reported to show equivalence to
commercially available tests.

Anteo has started Milestone 2, which is focused on building further robustness and
reproducibility of its conjugates while progressively driving for maximum achievable assay
sensitivity. “Anteo expects to provide the partnership with a robust technical and
commercial solution that can be applied to many different assays and not just the target
assay currently being investigated,” said Anteo Technologies Head of R&D Charlie Huang.
Milestone 2 is scheduled to be completed by next quarter.

The DMTC Medical Countermeasures (MCM) program recognises the increasing important
need to create an integrated multidisciplinary network focussed on MCM product
development. Nplex Managing Director Dr Sacha Dopheide said, “First pass optimisation
indicates that Anteo’s conjugate and assay chemistry is performing above expectations with
a respectable signal to noise ratio. We are encouraged by the results on Milestone 1 and
look forward to seeing where Anteo can take their technology in this project.”
Anteo has a vision to provide functional nanometre-thin coatings and binders across
multiple industries and applications. In this area, we focus on improving the performance of
PoC platforms through integration of our technologies with our partners cutting edge
technologies and jointly achieve better clinical diagnostic outcomes for end customers.
The global market size for POC diagnostics alone is projected to reach $36.96 billion USD
by 2021*.

* Markets & Markets